Q1 2017 EPS Estimates for Arrowhead Research Corp. (ARWR) Increased by Analyst
Arrowhead Research Corp. (NASDAQ:ARWR) – Research analysts at Jefferies Group increased their Q1 2017 earnings per share estimates for shares of Arrowhead Research Corp. in a note issued to investors on Wednesday. Jefferies Group analyst E. Yang now expects that the brokerage will earn $0.18 per share for the quarter, up from their previous estimate of ($0.33). Jefferies Group also issued estimates for Arrowhead Research Corp.’s Q2 2017 earnings at ($0.34) EPS, Q3 2017 earnings at ($0.38) EPS, Q4 2017 earnings at ($0.42) EPS, FY2017 earnings at ($0.96) EPS, FY2018 earnings at ($1.18) EPS and FY2019 earnings at ($0.91) EPS.
Arrowhead Research Corp. (NASDAQ:ARWR) last posted its quarterly earnings data on Tuesday, August 9th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.05. The company earned $39.58 million during the quarter, compared to analysts’ expectations of $0.05 million. Arrowhead Research Corp. had a negative net margin of 48,980.81% and a negative return on equity of 100.50%. The firm’s revenue for the quarter was down 68.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.27) EPS.
A number of other equities research analysts have also issued reports on ARWR. Piper Jaffray Cos. decreased their target price on shares of Arrowhead Research Corp. from $13.00 to $8.00 and set an “overweight” rating for the company in a research note on Wednesday, August 10th. Cantor Fitzgerald initiated coverage on shares of Arrowhead Research Corp. in a report on Wednesday, August 17th. They set a “buy” rating and a $15.00 price target on the stock. William Blair initiated coverage on shares of Arrowhead Research Corp. in a report on Friday, August 19th. They issued an “outperform” rating on the stock. Finally, Chardan Capital reiterated a “buy” rating and issued a $10.00 target price on shares of Arrowhead Research Corp. in a report on Wednesday, September 7th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Arrowhead Research Corp. has an average rating of “Buy” and an average target price of $10.11.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/07/q1-2017-eps-estimates-for-arrowhead-research-corp-arwr-increased-by-analyst.html
Arrowhead Research Corp. (NASDAQ:ARWR) traded down 3.27% during trading on Friday, reaching $6.80. 523,331 shares of the company’s stock were exchanged. The company’s 50-day moving average is $7.20 and its 200-day moving average is $6.04. Arrowhead Research Corp. has a 1-year low of $3.07 and a 1-year high of $8.22. The company’s market capitalization is $413.10 million.
In other Arrowhead Research Corp. news, CFO Kenneth Allen Myszkowski sold 6,900 shares of the firm’s stock in a transaction on Tuesday, August 23rd. The shares were sold at an average price of $8.00, for a total value of $55,200.00. Following the sale, the chief financial officer now directly owns 128,789 shares in the company, valued at approximately $1,030,312. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 3.90% of the stock is currently owned by company insiders.
Hedge funds have recently modified their holdings of the stock. California Public Employees Retirement System acquired a new stake in shares of Arrowhead Research Corp. during the second quarter valued at $1,462,000. Point72 Asset Management L.P. acquired a new stake in shares of Arrowhead Research Corp. during the second quarter valued at $1,362,000. KCG Holdings Inc. acquired a new stake in shares of Arrowhead Research Corp. during the second quarter valued at $439,000. Emerald Acquisition Ltd. acquired a new stake in shares of Arrowhead Research Corp. during the second quarter valued at $390,000. Finally, Vanguard Group Inc. raised its stake in shares of Arrowhead Research Corp. by 2.6% in the second quarter. Vanguard Group Inc. now owns 2,446,346 shares of the company’s stock valued at $13,015,000 after buying an additional 62,229 shares during the period. Institutional investors and hedge funds own 33.92% of the company’s stock.
Arrowhead Research Corp. Company Profile
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. ARC-520 is designed to treat chronic hepatitis B virus (HBV) infection.
Receive News & Ratings for Arrowhead Research Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Research Corp. and related companies with MarketBeat.com's FREE daily email newsletter.